SEQUELA AND RISKS OF COVID-19 VACCINES

Authors

  • Wasfi Dhahir Abid ali Ass .prof department of basic science – college of nursing - university of Basrah
  • Mahfoud Falih Hasan Prof. department of basic science – college of nursing - university of Basrah
  • Semahir S, Hameed Ass,In department of basic science – college of nursing - university of Basrah
  • luay abdulwahid shihab Ass. prof department of basic science – college of nursing - university of Basrah

DOI:

https://doi.org/10.53555/nnmhs.v8i6.1300

Keywords:

COVID -19, risks,, sequela .nursing, vaccines

Abstract

 Billions of people around the world are vaccinated with the COVI19 vaccine. The virus that claimed the lives of millions of people of different races and ages, and the antiviral vaccine is an important means of preventing and protecting against infection for a period of time. Data  of  the  present study which conducted  in Basrah city southern of  Iraq , showed that male 46% of the  vaccinated participants were male  more than  female ,59% of  them between 23 -30 years of  age,72%  vaccinated with Pfizer and  most  of  them  showed  symptom for post vaccination after 1-6 day.  Fever significantly rise with Pfizer vaccine, post vaccinated complication correlated with persons have chronic diseases , post complications symptom  correlate  with age and  period, ,sex and work are not significant .

 

References

Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC (December 2020). "Coronavirus vaccine development: from SARS and MERS to COVID-19". Journal of Biomedical Science. 27 (1): 104. doi:10.1186/s12929-020-00695-2. 7749790. PMID 33341119.

Richie H, Ortiz-Ospina E, Beltekian D, Methieu E, Hasell J, Macdonald B, et al. (5 March 2020). "Coronavirus (COVID-19) Vaccinations – Statistics and Research". Our World in Data. Retrieved 7 February 2021.

Mullard A (November 2020). "How COVID vaccines are being divvied up around the world". Nature. doi:10.1038/d41586-020-03370-6. PMID 33257891. S2CID 227246811.

"Kazakhstan rolls out its own COVID-19 vaccine". Reuters. 27 April 2021. Retrieved 2 July 2021.

"FarsNews Agency Iran Licenses Emergency Injection of Home-Made Anti-Coronavirus Vaccine". Fars News Agency. 14 June 2021. Retrieved 25 August 2021.

"VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Retrieved 11 January 2021.

oronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 4 December 2021. Public Domain This article incorporates text from this source, which is in the public domain.

"Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020.

641.2004.01272.x. PMID 15479434. S2CID 154670.

"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu)". ClinicalTrials.gov. 12 May 2020. NCT04383574. Archived from the original on 11 October 2020. Retrieved 14 July 2020.

"Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)". ClinicalTrials.gov. 2 July 2020. NCT04456595. Archived from the original on 11 October 2020. Retrieved 3 August 2020.

PT. Bio Farma (10 August 2020). "A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia". Registri Penyakit Indonesia. Archived from the original on 11 October 2020. Retrieved 15 August 2020.

Chen W, Al Kaabi N (18 July 2020). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. Retrieved 15 August 2020.

Ivanova P (20 February 2021). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Retrieved 11 April 2021.

Published

2022-08-05